Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema

BMC Pulmonary Medicine

Volumn 13, Issue 1, 2013, Pages

  Tzouvelekis, Argyris ^a   Zacharis, George ^a   Oikonomou, Anastasia ^a   Mikroulis, Dimitrios ^a   Margaritopoulos, George ^b   Koutsopoulos, Anastasios ^a   Antoniadis, Antonis ^c   Koulelidis, Andreas ^a   Steiropoulos, Paschalis ^a   Boglou, Panagiotis ^a   Bakali, Matina ^a   Froudarakis, Marios ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b General Hospital of Kavala   (Greece)

^c General District Hospital of Serres   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CD20 ANTIGEN; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; JO 1 ANTIBODY; LA ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SCL 70 ANTIBODY; SM ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG EMPHYSEMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; SPIROMETRY; SURVIVAL;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, CD20; AUTOIMMUNITY; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; COMORBIDITY; EMPHYSEMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES;

EID: 84878004269     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-13-31     Document Type: Article

References (43)

1. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26:586-593. 10.1183/09031936.05.00021005, 16204587.
2. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med 2005, 172:1605-1606. 10.1164/ajrccm.172.12.1605, 16339012.
3. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest 2009, 136:1-2. 10.1378/chest.09-0538, 19584202.
4. Cottin V, Le PJ, Prevot G, Mal H, Humbert M, Simonneau G. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010, 35:105-111. 10.1183/09031936.00038709, 19643948.
5. Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011, 63:295-304. 10.1002/art.30077, 20936629.
6. Luzina IG, Todd NW, Iacono AT, Atamas SP. Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol 2008, 83:237-244.
7. Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006, 28:496-504. 10.1183/09031936.06.00032605, 16611657.
8. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991, 144:291-296. 10.1164/ajrccm/144.2.291, 1859050.
9. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125-133. 10.1056/NEJMoa030511, 14711911.
10. Spagnolo P, Del GC, Luppi F, Cerri S, Balduzzi S, Walters EH. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010, CD003134.
11. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007, 179:2592-2599.
12. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P. Global impairment of CD4 + CD25 + FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:1121-1130. 10.1164/rccm.200812-1936OC, 19342412.
13. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component?. Thorax 2003, 58:832-834. 10.1136/thorax.58.10.832, 1746486, 14514931.
14. Bonarius HP, Brandsma CA, Kerstjens HA, Koerts JA, Kerkhof M, Nizankowska-Mogilnicka E. Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history. Thorax 2011, 66:101-107. 10.1136/thx.2009.134171, 21047865.
15. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010, 36:116-121. 10.1183/09031936.00110109, 19926741.
16. Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011, 37:1503-1513. 10.1183/09031936.00148409, 21071471.
17. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med 2007, 176:691-697. 10.1164/rccm.200702-220OC, 1994238, 17556720.
18. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung 2010, 188:143-149. 10.1007/s00408-009-9226-7, 2837880, 20069430.
19. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. 10.1016/S0140-6736(11)60405-4, 21571362.
20. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087. 10.1056/NEJMoa1103690, 21992121.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
22. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088.
23. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989, 16:328-334.
24. Vitali C. Classification criteria for Sjogren's syndrome. Ann Rheum Dis 2003, 62:94-95. 10.1136/ard.62.1.94, 1754291, 12480687.
25. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
26. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254. 10.1164/rccm.200706-877OC, 18369202.
27. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008, 246:697-722. 10.1148/radiol.2462070712, 18195376.
28. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. 10.1164/rccm.2009-040GL, 21471066.
29. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304.
30. Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007, 176:1108-1119. 10.1164/rccm.200705-683OC, 17761615.
31. Tzouvelekis A, Zacharis G, Oikonomou A, Koulelidis A, Steiropoulos P, Froudarakis M. Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J 2012, 40:505-507. 10.1183/09031936.00216311, 22855473.
32. Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil?. Respir Res 2012, 13:3. 10.1186/1465-9921-13-3, 3282644, 22235752.
33. Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005, 171:1363-1370. 10.1164/rccm.200410-1349OC, 2718479, 15805183.
34. Isajevs S, Taivans I, Strazda G, Kopeika U, Bukovskis M, Gordjusina V. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J 2009, 33:61-67. 10.1183/09031936.00145307, 18684844.
35. Tzouvelekis A, Kostikas K, Bouros D. Autoimmunity and chronic obstructive pulmonary disease: thinking beyond cigarette smoke. Am J Respir Crit Care Med 2012, 185:1248-1249.
36. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:2445-2454. 10.1056/NEJMra0804752, 19494220.
37. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600-1605.
38. Gomez-Puerta JA, Hernandez-Rodriguez J, Lopez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009, 136:1101-1111. 10.1378/chest.08-3043, 19809051.
39. Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, Nicholson AG. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012, 39:661-668. 10.1183/09031936.00174910, 21920896.
40. Suda T, Kono M, Nakamura Y, Enomoto N, Kaida Y, Fujisawa T. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med 2010, 104:1527-1534. 10.1016/j.rmed.2010.04.022, 20483576.
41. Schwarz MI, Mortenson RL, Colby TV, Waldron JA, Lynch DA, Hutt MP. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993, 148:507-511. 10.1164/ajrccm/148.2.507, 8102044.
42. Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000, 55:502-510. 10.1136/thorax.55.6.502, 1745770, 10817800.
43. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011, 13:R38. 10.1186/ar3271, 3132017, 21366908.